IRP Researchers Develop Drug to Recapture Immune Cells Hijacked by Tumors
Friday, June 3, 2022
In the 1958 cult classic The Blob, a giant gelatinous creature from outer space lands on Earth and begins engulfing a small town and everything in it. While that may sound far out, a similar entity within our bodies does much the same thing, but for good instead of ill. These Pac-Man-like blobs are called macrophages — Greek for ‘big eaters’ — and they serve a vital role in keeping us healthy by clearing away dead cells and digesting foreign invaders like bacteria and cancer cells.
However, cancer cells aren’t content to just let themselves be eaten. They have evolved ways to overwhelm and commandeer the immune system, redirecting immune cells to support tumor growth rather than suppress it. Although highly personalized ‘immunotherapies’ that reboot the immune response and harness it to fight cancer have made significant advances in treating some forms of the disease, most cancers do not respond to these treatments. Fortunately, reinforcements are on the way: IRP senior investigators Udo Rudloff, M.D., Ph.D., and Juan Marugan, Ph.D., have identified a way to reclaim the loyalty of macrophages that are aiding and abetting tumors, turning them back into the cancer-consuming gluttons they were meant to be. Importantly, this approach may be effective on a broader array of cancers than other immunotherapies.
Cells From Bone Marrow Calm Damaging Immune Response
Tuesday, April 28, 2020
In patients with the inflammatory disease sarcoidosis, the body’s own immune cells rampage around the body like The Incredible Hulk set loose in a city, attacking both harmful pathogens and our own tissues. However, just like the Black Widow can calm The Hulk down and return him to human form in the Avengers films, cells isolated from our bone marrow may be able to change certain immune cells from a damaging state to a benign one, according to new IRP research.
Discovery Could Improve Therapy for Multiple Autoimmune Diseases
Tuesday, August 20, 2019
Hiding among YouTube’s vast collection of cooking demos and funny cat videos are clips of patients and their advocates designed to raise awareness of specific diseases. It was just such a video that led IRP Senior Investigator Peter Grayson, M.D., M.Sc., to begin studying an extremely rare illness called deficiency of adenosine deaminase 2, or DADA2 for short. The recently published findings of that research could help improve treatment not just for patients with DADA2 but also many more individuals with similar ailments.
Thursday, February 28, 2019
The NIH’s main campus in Bethesda, Maryland, may have the look and feel of a university campus, but the world-renowned research institution does not grant credentials like an M.D. or Ph.D. Instead, the Graduate Partnerships Program offers graduate students from schools around the world the opportunity to complete research for their Ph.D. dissertations in IRP labs while pursuing advanced degrees from their ‘host’ institutions.
Potential biomarker may contribute to personalized treatments
Tuesday, February 5, 2019
Until recently, medical treatment has largely been one-size-fits-all, with doctors unable to separate patients into distinct groups that might benefit more or less from a particular approach. However, researchers are increasingly finding that individuals with the same disease can differ markedly in ways that might one day influence their care. A recent IRP study has identified a particular molecule that may have just such an impact for patients with damaged lungs.